ArticleScientific reports2025
Investigating the role of MYLK2 in breast cancer prognosis and assessing its clinical application value.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveThis study aims to investigate the mechanistic role of MYLK2 (myosin light chain kinase 2) in breast cancer and assess its potential as a prognostic biomarker for clinical applications.
methodsWe performed a comprehensive analysis using gene expression data from breast cancer patients in The Cancer Genome Atlas (TCGA) database. Kaplan-Meier survival analysis and multivariate Cox regression models were employed to evaluate the association between MYLK2 expression levels and patient survival outcomes.
resultsOur findings demonstrate that MYLK2 is significantly overexpressed in tumor tissues compared to normal adjacent tissues (P < 0.05). Kaplan-Meier survival analysis revealed that high MYLK2 expression correlates with poorer overall survival (OS), progression-free survival (PFS), and disease-specific survival (DSS) (P < 0.05). Furthermore, multivariate Cox regression analysis identified MYLK2 as an independent prognostic factor for adverse outcomes in breast cancer patients.
conclusionThis study elucidates the critical biological functions of MYLK2 in breast cancer, suggesting that it may serve as a promising prognostic biomarker. These findings provide new insights for early diagnosis and treatment strategies in breast cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.